|
1
|
Rimawi MF, Schiff R and Osborne CK:
Targeting HER2 for the Treatment of Breast Cancer. Annu Rev Med.
66:111–128. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kasprzyk PG, Song SU, Di Fiore PP and King
CR: Therapy of an animal model of human gastric cancer using a
combination of anti-erbB-2 monoclonal antibodies. Cancer Res.
52:2771–2776. 1992.PubMed/NCBI
|
|
3
|
Batra JK, Kasprzyk PG, Bird RE, Pastan I
and King CR: Recombinant anti-erbB2 immunotoxins containing
Pseudomonas exotoxin. Proc Natl Acad Sci USA. 89:5867–5871.
1992.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Jia LT, Zhang LH, Yu CJ, Zhao J, Xu YM,
Gui JH, Jin M, Ji ZL, Wen WH, Wang CJ, et al: Specific tumoricidal
activity of a secreted proapoptotic protein consisting of HER2
antibody and constitutively active caspase-3. Cancer Res.
63:3257–3262. 2003.PubMed/NCBI
|
|
5
|
Ou-Yang Q, Yan B, Li A, Hu ZS, Feng JN,
Lun XX, Zhang MM, Zhang MD, Wu KC, Xue FF, et al: Construction of
humanized anti-HER2 single-chain variable fragments (husFvs) and
achievement of potent tumor suppression with the reconstituted
husFv-Fdt-tBid immunoapoptotin. Biomaterials. 178:170–182.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mazor R, Onda M and Pastan I:
Immunogenicity of therapeutic recombinant immunotoxins. Immunol
Rev. 270:152–164. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sheedy C, Mackenzie CR and Hall JC:
Isolation and affinity maturation of hapten-specific antibodies.
Biotechnol Adv. 25:333–352. 2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Briney B, Sok D, Jardine JG, Kulp DW, Skog
P, Menis S, Jacak R, Kalyuzhniy O, de Val N, Sesterhenn F, et al:
Tailored immunogens direct affinity maturation toward HIV
neutralizing. Cell. 166:1459–1464.e11. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Prassler J, Steidl S and Urlinger S: In
vitro affinity maturation of HuCAL antibodies: Complementarity
determining region exchange and RapMAT technology. Immunotherapy.
1:571–583. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Foote J and Winter G: Antibody framework
residues affecting the conformation of the hypervariable loops. J
Mol Biol. 224:487–499. 1992.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Teplyakov A, Obmolova G, Malia TJ,
Raghunathan G, Martinez C, Fransson J, Edwards W, Connor J,
Husovsky M, Beck H, et al: Structural insights into humanization of
anti-tissue factor antibody 10H10. MAbs. 10:269–277.
2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhang L, Cai QY, Cai ZX, Fang Y, Zheng CS,
Wang LL, Lin S, Chen DX and Peng J: Interactions of bovine serum
albumin with anti-cancer compounds using a ProteOn XPR36 array
biosensor and molecular docking. Molecules. 21(1706)2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yan B, Ouyang Q, Zhao Z, Cao F, Wang T,
Jia X, Meng Y, Jiang S, Liu J, Chen R, et al: Potent killing of
HBV-related hepatocellular carcinoma by a chimeric protein of
anti-HBsAg single-chain antibody and truncated Bid. Biomaterials.
34:4880–4889. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
LuCore SD, Litman JM, Powers KT, Gao S,
Lynn AM, Tollefson WT, Fenn TD, Washington MT and Schnieders MJ:
Dead-end elimination with a polarizable force field repacks PCNA
structures. Biophys J. 109:816–826. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tiller KE, Chowdhury R, Li T, Ludwig SD,
Sen S, Henry KA and Tessier PM: Facile affinity maturation of
antibody variable domains using natural diversity mutagenesis.
Front Immunol. 8(986)2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chothia C and Lesk AM: Canonical
structures for the hypervariable regions of immunoglobulins. J Mol
Biol. 196:901–917. 1987.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Moreira GMSG, Fuhner V and Hust M: Epitope
mapping by phage display. Methods Mol Biol. 1701:497–518.
2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tahara T, Kuwaki T, Matsumoto A, Morita H,
Watarai H, Inagaki Y, Ohashi H, Ogami K, Miyazaki H and Kato T:
Neutralization of biological activity and inhibition of receptor
binding by antibodies against human thrombopoietin. Stem Cells.
16:54–60. 1998.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wright GJ, Cherwinski H, Foster-Cuevas M,
Brooke G, Puklavec MJ, Bigler M, Song Y, Jenmalm M, Gorman D,
McClanahan T, et al: Characterization of the CD200 receptor family
in mice and humans and their interactions with CD200. J Immunol.
171:3034–3046. 2013.PubMed/NCBI View Article : Google Scholar
|
